Atrial Fibrillation Market
Description
Atrial Fibrillation Market Summary
The global atrial fibrillation market size was estimated at USD 29.52 billion in 2025 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.52% from 2026 to 2033. The market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.
Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.
The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.
Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI’s potential to transform electrophysiology by boosting clinical confidence and procedural precision.
The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.
The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF’s escalating clinical and economic impact in the region.
Global Atrial Fibrillation Market Report Segmentation
This report forecasts revenue growth and provides a global, regional, and country level analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment, end use, and region:
The global atrial fibrillation market size was estimated at USD 29.52 billion in 2025 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.52% from 2026 to 2033. The market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.
Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.
The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.
Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI’s potential to transform electrophysiology by boosting clinical confidence and procedural precision.
The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.
The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF’s escalating clinical and economic impact in the region.
Global Atrial Fibrillation Market Report Segmentation
This report forecasts revenue growth and provides a global, regional, and country level analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment, end use, and region:
- Treatment Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmacological Treatment
- Anti-arrhythmic Drugs
- Anticoagulant Drugs
- Non-Pharmacological Treatment
- Catheter Ablation
- Radiofrequency
- HIFU
- Cryoablation
- Microwave
- Laser
- Maze Surgery
- Electric Cardioversion
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Information Procurement
- 1.2. Information or Data Analysis
- 1.3. Market Scope & Segment Definition
- 1.4. Market Model
- 1.4.1. Market Study, By Company Market Share
- 1.4.2. Regional Analysis
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Trends and Outlook
- 3.4. Market Dynamics
- 3.5. Market Restraint Analysis
- 3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
- 3.6.2. Porter’s Five Forces Analysis
- Chapter 4. Product Business Analysis
- 4.1. Ferritin Testing Market: Product Movement Analysis
- 4.2. Instrument
- 4.2.1. Instrument Market, 2021 - 2033 (USD Million)
- 4.3. Reagent
- 4.3.1. Reagent Market, 2021 - 2033 (USD Million)
- 4.4. Kits
- 4.4.1. Kits Market, 2021 - 2033 (USD Million)
- Chapter 5. Application Business Analysis
- 5.1. Ferritin Testing Market: Application Movement Analysis
- 5.2. Anemia
- 5.2.1. Anemia Market, 2021 - 2033 (USD Million)
- 5.3. Hemochromatosis
- 5.3.1. Hemochromatosis Market, 2021 - 2033 (USD Million)
- 5.4. Lead Poisoning
- 5.4.1. Lead Poisoning Market, 2021 - 2033 (USD Million)
- 5.5. Pregnancy
- 5.5.1. Pregnancy Market, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 6. End-use Business Analysis
- 6.1. Ferritin Testing Market: End-use Movement Analysis
- 6.2. Hospitals
- 6.2.1. Hospitals Market, 2021 - 2033 (USD Million)
- 6.3. Diagnostic Laboratories
- 6.3.1. Diagnostic Laboratories Unit Market, 2021 - 2033 (USD Million)
- Chapter 7. Regional Business Analysis
- 7.1. Ferritin Testing Market Share, By Region, 2025 & 2033
- 7.2. North America
- 7.2.1. North America Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Target Disease Prevalence
- 7.2.2.3. Competitive Scenario
- 7.2.2.4. Regulatory Framework
- 7.2.2.5. Reimbursement Scenario
- 7.2.2.6. U.S. Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Competitive Scenario
- 7.2.3.4. Regulatory Framework
- 7.2.3.5. Reimbursement Scenario
- 7.2.3.6. Canada Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Target Disease Prevalence
- 7.2.4.3. Competitive Scenario
- 7.2.4.4. Regulatory Framework
- 7.2.4.5. Reimbursement Scenario
- 7.2.4.6. Mexico Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.2. Germany
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Competitive Scenario
- 7.3.2.4. Regulatory Framework
- 7.3.2.5. Reimbursement Scenario
- 7.3.2.6. Germany Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. Reimbursement Scenario
- 7.3.3.6. UK Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Reimbursement Scenario
- 7.3.4.6. France Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Competitive Scenario
- 7.3.5.4. Regulatory Framework
- 7.3.5.5. Reimbursement Scenario
- 7.3.5.6. Italy Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Competitive Scenario
- 7.3.6.4. Regulatory Framework
- 7.3.6.5. Reimbursement Scenario
- 7.3.6.6. Spain Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Competitive Scenario
- 7.3.7.4. Regulatory Framework
- 7.3.7.5. Reimbursement Scenario
- 7.3.7.6. Denmark Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Competitive Scenario
- 7.3.8.4. Regulatory Framework
- 7.3.8.5. Reimbursement Scenario
- 7.3.8.6. Sweden Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Competitive Scenario
- 7.3.9.4. Regulatory Framework
- 7.3.9.5. Reimbursement Scenario
- 7.3.9.6. Norway Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Regulatory Framework
- 7.4.2.5. Reimbursement Scenario
- 7.4.2.6. Japan Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Reimbursement Scenario
- 7.4.3.6. China Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. Reimbursement Scenario
- 7.4.4.6. India Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. Reimbursement Scenario
- 7.4.5.6. South Korea Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Reimbursement Scenario
- 7.4.6.6. Australia Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Reimbursement Scenario
- 7.4.7.6. Thailand Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Regulatory Framework
- 7.5.2.5. Reimbursement Scenario
- 7.5.2.6. Brazil Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. Reimbursement Scenario
- 7.5.3.6. Argentina Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Regulatory Framework
- 7.6.2.5. Reimbursement Scenario
- 7.6.2.6. South Africa Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. Reimbursement Scenario
- 7.6.3.6. Saudi Arabia Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Regulatory Framework
- 7.6.4.5. Reimbursement Scenario
- 7.6.4.6. UAE Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Regulatory Framework
- 7.6.5.5. Reimbursement Scenario
- 7.6.5.6. Kuwait Ferritin Testing Market, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. Eurolyser Diagnostica GmbH
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Collection Site Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Cortez Diagnostics Inc
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Collection Site Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Pointe Scientific, Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Collection Site Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Humankind Ventures Ltd
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Collection Site Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Aviva Systems Biology Corporation
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Collection Site Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. bioMérieux S.A
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Collection Site Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Abnova Corporation
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Collection Site Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Cosmic Scientific Technologies
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Collection Site Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. CTK Biotech, Inc
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Collection Site Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. Thermo Fisher Scientific Inc.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Collection Site Benchmarking
- 8.4.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
